For: |
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Fourteen- |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i26/8132.htm |
Number | Citing Articles |
1 |
Neus Muñoz, Jordi Sánchez‐Delgado, Mireia Baylina, Ignasi Puig, Sheila López‐Góngora, David Suarez, Xavier Calvet. Systematic review, meta‐analysis, and meta‐regression: Successful second‐line treatment forHelicobacter pylori. Helicobacter 2018; 23(3) doi: 10.1111/hel.12488
|
2 |
Sung Bum Kim, Si Hyung Lee, Kyeong Ok Kim, Byung Ik Jang, Tae Nyeun Kim. Ten-day Sequential TherapyversusBismuth Based Quadruple Therapy as Second Line Treatment forHelicobacter pyloriInfection. The Korean Journal of Gastroenterology 2015; 66(5): 261 doi: 10.4166/kjg.2015.66.5.261
|
3 |
Pei‐Ying Zou, Jie Hu, Jing‐Tao Zhao, Zhe Zhao, Hao Mei, Jing Yang, Yang‐Jie Zhu, Yi Zhang, Chun‐Hui Lan. 10‐Day and 14‐day high‐dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis. Helicobacter 2021; 26(5) doi: 10.1111/hel.12833
|
4 |
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Hae Koo Kim, Young Dal Lee. Second-line bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication and impact of diabetes. World Journal of Gastroenterology 2017; 23(6): 1059-1066 doi: 10.3748/wjg.v23.i6.1059
|
5 |
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. Journal of Primary Care & Community Health 2021; 12 doi: 10.1177/21501327211014087
|
6 |
Varocha Mahachai, Ratha‐korn Vilaichone, Rapat Pittayanon, Jarin Rojborwonwitaya, Somchai Leelakusolvong, Monthira Maneerattanaporn, Peranart Chotivitayatarakorn, Sombat Treeprasertsuk, Chomsri Kositchaiwat, Pises Pisespongsa, Pisaln Mairiang, Aziz Rani, Alex Leow, Swe Mon Mya, Yi‐Chia Lee, Sengdao Vannarath, Bouachanh Rasachak, Oung Chakravuth, Moe Myint Aung, Tiing‐Leong Ang, Jose D Sollano, Duc Trong Quach, Inchaya Sansak, Olarn Wiwattanachang, Piyathida Harnsomburana, Ari Fahrial Syam, Yoshio Yamaoka, Kwong‐Ming Fock, Khean‐Lee Goh, Kentaro Sugano, David Graham. Helicobacter pylori management in ASEAN: The Bangkok consensus report. Journal of Gastroenterology and Hepatology 2018; 33(1): 37 doi: 10.1111/jgh.13911
|
7 |
Ji-Young Jeon, Sun-Young Kim, Seol Ju Moon, Kyeongmin Oh, Jiwon Lee, Bongtae Kim, Geun Seog Song, Min-Gul Kim. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clinical Therapeutics 2021; 43(4): 722 doi: 10.1016/j.clinthera.2021.01.026
|
8 |
Kiwon Shin, Min-Jae Cho, Jung-Hwan Oh, Chul-Hyun Lim. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. Journal of Clinical Medicine 2021; 10(15): 3273 doi: 10.3390/jcm10153273
|
9 |
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure inHelicobacter pyloriEradication. The Korean Journal of Gastroenterology 2018; 71(4): 196 doi: 10.4166/kjg.2018.71.4.196
|
10 |
Ji Yeon Kim, Sun-Young Lee, Hyobin Kim, Jeong Hwan Kim, In-Kyung Sung, Hyung Seok Park. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-LineHelicobacter PyloriEradication Therapy Administered with Bismuth. Yonsei Medical Journal 2021; 62(8): 708 doi: 10.3349/ymj.2021.62.8.708
|